By Denny Jacob
Scholar Rock's biologics license application for apitegromab was accepted by the Food and Drug Administration.
The late-stage biopharmaceutical company said the regulator will review the application under priority review and has assigned a Prescription Drug User Fee Act target action date of Sept. 22.
Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy.
Scholar Rock said it has also submitted and received validation for its marketing authorization application to the European Medicines Agency for apitegromab to treat SMA.
The Cambridge, Mass., company is planning for a U.S. commercial launch upon approval in 2025, with European launch expected in 2026, in anticipation of potential regulatory approvals.
Shares ticked up 3.5% to $34.99 in premarket trading. The stock has more than doubled over the last year.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 25, 2025 08:44 ET (12:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。